CARDIOVASCULAR OUTCOMES WITH NEBIVOLOL, ATENOLOL AND METOPROLOL IN PATIENTS WITH HYPERTENSION: A LARGE, RETROSPECTIVE, PROPENSITY SCORE-MATCHED COHORT STUDY

Introduction: β-blockers reduce risk of cardiovascular (CV) events, but comparative CV event risk between the vasodilatory β1-selective antagonist/β3 agonist nebivolol and non-vasodilatory β1-blockers atenolol and metoprolol is unknown. Objective: To compare hospitalization risk due to CV